WSO - July 2023 - 686

686
International Journal of Stroke 18(6)
Table 3. Results of multivariable regression model for favorable functional outcome (modified Rankin Scale 0-2) at discharge.
Adjusted odds ratio 95% Confidence interval
Neurologic deterioration
NIHSS score on admission (per point increase)
Female
Age
Dual antiplatelet with loading dose (single antiplatelet as reference)
Thrombolysis
Length of hospitalization
Delay time from onset to hospitalization (h)
Glucose on admission (mmol/L)
SBP dropping ⩾ 20 mm Hg
PremRS
NIHSS: National Institutes of Health Stroke Scale; SBP: systolic blood pressure.
induced-hypertension therapy may improve motor function.9
However, these studies had their limitations: some studies
did not report the blood pressure value,12 or the admission
blood pressure between the groups was relatively low and
similar, and the sample size was small,9 and one study
excluded END patients occurred beyond 24 h after admission
that could underestimate the influence of high SBP on
END.3 In our large cohort study, we found that higher
SBP(⩾160 mm Hg) is significantly associated with END,
which agrees with some other previous studies.7,10,13 The
explanation may be that acute hypertension could induce
penetrating artery lipohyalinosis, which is the characteristic
vascular pathology of lacunar stroke,6 and clinical symptoms
of brain infarction often developed during periods of an
increase in blood pressure,14 hypertension also could lead to
cerebral arterial spasm,15 which may result in lacunar stroke
and END. Concerns may be raised that hypertension may be
a response to END to improve cerebral perfusion; however,
hypertension may also reduce cerebral blood perfusion and,
finally, lead to END. One study using 133Xe inhalation for
cerebral perfusion assessment found reductions in cerebral
blood perfusion in hypertensive patients,16 another SPECTbased
study in healthy older men reported reduced CBF with
increasing blood pressure.17 And interestingly, lowering
hypertension could increase blood flow velocity in the middle
cerebral artery,18 and intensive blood pressure lowering
raised cerebral blood flow in older patients with hypertension.19
However, caution must be taken that, we did not analyze
the perfusion data and could not directly confirm if
reduced perfusion may be relevant to END, and the mechanism
of how acute hypertension affected the extent of infarction
and functional outcome is still uncertain.
International Journal of Stroke, 18(6)
Since higher admission SBP increased the risk of END,
BP lowering may prevent the occurrence of END. The most
concern has been raised that BP lowering may exacerbate
cerebral hypoperfusion,20 which could underlie END.4
However, the result was not replicated by another study,21
and one RCT further demonstrated that even intensive BP
lowering did not reduce cerebral perfusion in severe small
vessel disease,22 and blood pressure lowering did not exacerbate
the functional outcome of lacunar stroke.23 Similarly,
we did not find BP-lowering-induced END in our study.
Furthermore, since most END occurred within 3 days after
admission, we explored the effect of SBP dropping
(⩾20 mm Hg) within 3 days on END, and found that SBP
dropping (⩾20 mm Hg) was significantly inversely associated
with END.
Prior studies revealed that infarction location in ventral
pons predicted END3,24; however, another MRI-based study
did not find a significant influence of pons infarction on
END occurrence.12 Similarly, we also find no significant
association between ventral pons lacunar stroke and END.
Interestingly, we found thalamic lacunar stroke was
inversely associated with END, and this phenomenon was
also seen in the above MRI-based study, which found that
thalamic lacunar strokes had the lowest risk for END occurrence.12
One explanation may be that thalamus is a sensory
organ, so even if the infarction progressed, it cannot be
reflected by motor dysfunction. However, the mechanism
underlying this observation is unclear and the association
needs further investigation.
Unlike a previous study which suggested that dual antiplatelet
protected lacunar stroke patients from END occurrence,3
we did not find a significant influence of dual
12.374
1.488
1.296
1.017
0.815
0.395
0.989
0.997
0.994
1.058
1.119
6.881-22.254
1.359-1.629
0.451-1.320
0.995-1.040
0.478-1.389
0.120-1.298
0.955-1.026
0.993-1.001
0.936-1.055
0.623-2.011
0.623-2.011
p-value
<0.001
<0.001
0.344
0.126
0.451
0.126
0.565
0.194
0.833
0.844
0.707

WSO - July 2023

Table of Contents for the Digital Edition of WSO - July 2023

Contents
WSO - July 2023 - Cover1
WSO - July 2023 - Cover2
WSO - July 2023 - 627
WSO - July 2023 - Contents
WSO - July 2023 - 629
WSO - July 2023 - 630
WSO - July 2023 - 631
WSO - July 2023 - 632
WSO - July 2023 - 633
WSO - July 2023 - 634
WSO - July 2023 - 635
WSO - July 2023 - 636
WSO - July 2023 - 637
WSO - July 2023 - 638
WSO - July 2023 - 639
WSO - July 2023 - 640
WSO - July 2023 - 641
WSO - July 2023 - 642
WSO - July 2023 - 643
WSO - July 2023 - 644
WSO - July 2023 - 645
WSO - July 2023 - 646
WSO - July 2023 - 647
WSO - July 2023 - 648
WSO - July 2023 - 649
WSO - July 2023 - 650
WSO - July 2023 - 651
WSO - July 2023 - 652
WSO - July 2023 - 653
WSO - July 2023 - 654
WSO - July 2023 - 655
WSO - July 2023 - 656
WSO - July 2023 - 657
WSO - July 2023 - 658
WSO - July 2023 - 659
WSO - July 2023 - 660
WSO - July 2023 - 661
WSO - July 2023 - 662
WSO - July 2023 - 663
WSO - July 2023 - 664
WSO - July 2023 - 665
WSO - July 2023 - 666
WSO - July 2023 - 667
WSO - July 2023 - 668
WSO - July 2023 - 669
WSO - July 2023 - 670
WSO - July 2023 - 671
WSO - July 2023 - 672
WSO - July 2023 - 673
WSO - July 2023 - 674
WSO - July 2023 - 675
WSO - July 2023 - 676
WSO - July 2023 - 677
WSO - July 2023 - 678
WSO - July 2023 - 679
WSO - July 2023 - 680
WSO - July 2023 - 681
WSO - July 2023 - 682
WSO - July 2023 - 683
WSO - July 2023 - 684
WSO - July 2023 - 685
WSO - July 2023 - 686
WSO - July 2023 - 687
WSO - July 2023 - 688
WSO - July 2023 - 689
WSO - July 2023 - 690
WSO - July 2023 - 691
WSO - July 2023 - 692
WSO - July 2023 - 693
WSO - July 2023 - 694
WSO - July 2023 - 695
WSO - July 2023 - 696
WSO - July 2023 - 697
WSO - July 2023 - 698
WSO - July 2023 - 699
WSO - July 2023 - 700
WSO - July 2023 - 701
WSO - July 2023 - 702
WSO - July 2023 - 703
WSO - July 2023 - 704
WSO - July 2023 - 705
WSO - July 2023 - 706
WSO - July 2023 - 707
WSO - July 2023 - 708
WSO - July 2023 - 709
WSO - July 2023 - 710
WSO - July 2023 - 711
WSO - July 2023 - 712
WSO - July 2023 - 713
WSO - July 2023 - 714
WSO - July 2023 - 715
WSO - July 2023 - 716
WSO - July 2023 - 717
WSO - July 2023 - 718
WSO - July 2023 - 719
WSO - July 2023 - 720
WSO - July 2023 - 721
WSO - July 2023 - 722
WSO - July 2023 - 723
WSO - July 2023 - 724
WSO - July 2023 - 725
WSO - July 2023 - 726
WSO - July 2023 - 727
WSO - July 2023 - 728
WSO - July 2023 - 729
WSO - July 2023 - 730
WSO - July 2023 - 731
WSO - July 2023 - 732
WSO - July 2023 - 733
WSO - July 2023 - 734
WSO - July 2023 - 735
WSO - July 2023 - 736
WSO - July 2023 - 737
WSO - July 2023 - 738
WSO - July 2023 - 739
WSO - July 2023 - 740
WSO - July 2023 - 741
WSO - July 2023 - 742
WSO - July 2023 - 743
WSO - July 2023 - 744
WSO - July 2023 - 745
WSO - July 2023 - 746
WSO - July 2023 - 747
WSO - July 2023 - 748
WSO - July 2023 - 749
WSO - July 2023 - 750
WSO - July 2023 - 751
WSO - July 2023 - 752
WSO - July 2023 - 753
WSO - July 2023 - 754
WSO - July 2023 - 755
WSO - July 2023 - 756
WSO - July 2023 - Cover3
WSO - July 2023 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com